surmount-1 trial tirzepatide obesity without diabetes weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Nutritional status with tirzepatide in

To view or add a comment, sign in The Next Chapter in Obesity Care: Beyond Injections with New Oral GLP-1s and Landmark WHO Guidelines The landscape of obesity medicine is undergoing a seismic shift

retmenolu O, Ssl AE, Ycel T, nerci TM, ahin A

Pregnant and nursing people should avoid it

Visceral fat is associated with increased risk of: cardiovascular disease insulin resistance type 2 diabetes metabolic syndrome Research suggests tirzepatide can significantly reduce visceral fat levels, which may improve overall metabolic health

Unlike other causes, cancer-related bruising often worsens progressively and occurs alongside unexplained weight loss, night sweats, or swollen lymph nodes